Combined treatment in Ramsay Hunt syndrome: evaluation of clinic and prognosis

Ramsay Hunt sendromunda kombine tedavi: Klinik ve prognozun değerlendirilmesi

Ercan Pınar, Abdulkadir İmre, Yüksel Olgun, Ahmet Ata Ece, Murat Songu, Hale Aslan

Department of Otorhinolaryngology, Izmir Katip Çelebi University Atatürk Training and Research Hospital, Izmir, Turkey

Abstract

Objective: We retrospectively analysed clinical characteristics, treatment and outcomes of the patients with Ramsay Hunt syndrome.

Methods: Twelve patients with Ramsay Hunt syndrome were analysed retrospectively. Data recorded included sex, age, time from first onset to initial treatment and clinical outcomes. The House-Brackmann scale was used to assess initial facial nerve dysfunction and final facial nerve impairment. All patients were treated with oral steroids and oral acyclovir.

Results: There were 7 male and 5 female patients. Mean age was 59 (range: 21 to 68) years. The main symptom was acute facial palsy. House-Brackmann classification of facial nerve function ranged from grade III to VI before treatment. The median baseline House-Brackmann grade was 4.5 and it was 2.33 after the treatment in all patients. Recovery rate of facial palsy was lower in patients with House-Brackmann grades V and VI.

Conclusion: In this syndrome, the prognosis of facial palsy depends on the initial symptoms and clinical findings. The prognosis was poorer in severe palsy and patients with comorbid disease(s).

Keywords: Ramsay Hunt syndrome, treatment, prognosis.

Ramsay Hunt syndrome (RHS) is a disease with involvement of the seventh and eighth cranial nerves and characterized by acute facial palsy and inner ear dysfunction with a herpetic eruption on the auricula and external ear canal. Ramsay Hunt reported the first case in 1907. This syndrome is caused by reactivation of the latent varicella zoster virus in the geniculate ganglion of the facial nerve.¹

This syndrome represents the second most common cause of atraumatic peripheral facial palsy. It is responsible for 2–10% of all cases of acute peripheral facial palsy.² The treatment of this syndrome is empiric. Various authors have reported several treatment protocols including corticosteroids, vasodilators and antiviral agents.³⁻⁴ The present study describes the clinical presentation, treatment and clinical outcomes of this rare disease.
Materials and Methods

This retrospective study included 12 patients who presented with RHS between March 2006 and October 2014. Patients were diagnosed with Ramsay Hunt syndrome if they had peripheral facial palsy and vesicles around the ear. Data recorded included sex, age, time from the first onset to initial treatment and clinical outcomes. The House-Brackmann scale was used to assess initial facial nerve dysfunction and final facial nerve impairment. All patients underwent electroneurography (ENoG) 3 days after onset of palsy and all were followed up with electromyography (EMG) 3 weeks after the onset. Patients were followed up until recovery or for 6 months. Recovery was defined as attainment of House-Brackmann grade I or II.

Pure tone audiometry and neurology consultation was performed in all patients before treatment to assess the eight and other cranial nerve functions. Magnetic resonance imaging (MRI) was also performed.

All patients had low-salt diet. Patients were treated with oral steroids (1 mg/kg) by tapering dose regimen. Oral acyclovir (4000 mg/d for 7 days) was combined with oral steroids. Diabetic patients received the same dose of steroids under the medical care of an endocrinologist.

Results

There were seven male and five female patients in this retrospective study with a median age of 59 (range: 21 to 68) years. All patients admitted to our clinic within 2–5 days after the onset of the symptoms and received the treatment protocol. The median initial House-Brackmann grade was 4.5, while it was 2.33 after the treatment in all patients. Hearing loss and rotational vertigo were seen in six patients. Patients’ characteristics are shown in Table 1.

Overall recovery rate was 75% in this study. Recovery rate was lower in patients with an ENoG of >90% compared with ENoG <90%. Similarly, worse initial facial palsy was associated with lower recovery rate. Initial House-Brackman grade V or more had lower recovery rates. Recovery rate was 83.3% in patients with House-Brackmann grade ≤4; however, recovery rate was 33.3% in grades ≥V. Five patients had comorbid diseases (diabetes mellitus, hypertension). Patients with comorbid disease(s) had also lower recovery rates (Table 2).

Discussion

The standard treatment of RSH syndrome is corticosteroid and antiviral therapy. Corticosteroid therapy relieves pain, reduces vertigo, decreases the incidence of postherpetic neuralgia. It also reduces facial nerve inflammation and edema. Acyclovir, a synthetic acyclic purine nucleoside analog, is a selective inhibitor of herpes simplex virus types 1 and 2. [6]

Combined therapy is the treatment of choice in RSH syndrome. Uscategui et al. demonstrated a statistically significant difference between combined acyclovir–corticosteroid therapy and treatment with corticosteroids alone. [7] Similarly, Kinishi et al. reported that median recovery rate from facial palsy was 62% in patients treated with corticosteroids alone, however, with both acyclovir and steroid therapy, the receive rate was 90 percent. [6] The recovery rate was 84% in the study by Lee et al. [8] In our study, we treated our patients with combined therapy and the overall recovery rate was 75 percent.

We found that initial palsy episodes with lower grades of palsy were associated with a higher recovery rate. The median initial House-Brackmann grade was 4.5. House-Brackmann grade was 2.33 after the treatment. Recovery rate was lower in patients with grade V or more compared with mild cases. Similar to our results, Ko et al. and

<table>
<thead>
<tr>
<th>Patients (n=12)</th>
<th>Recovery rate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HB III–IV (n=6)</td>
<td>83.3%</td>
</tr>
<tr>
<td>HB V–VI (n=6)</td>
<td>33.3%</td>
</tr>
<tr>
<td>ENoG &gt;90% (n=8)</td>
<td>87.5%</td>
</tr>
<tr>
<td>ENoG &lt;90% (n=4)</td>
<td>50%</td>
</tr>
<tr>
<td>Comorbid disease Yes: 5 (41.6%)</td>
<td>80%</td>
</tr>
<tr>
<td>No: 7 (58.3%)</td>
<td>71.4%</td>
</tr>
</tbody>
</table>

Table 1. Characteristics of patients with Ramsay Hunt syndrome.

Table 2. Recovery rates of patients after treatment.
Zainine et al. found that incomplete paralysis had higher recovery rates.\textsuperscript{[4,9]} Coulson et al. also reported that improvement was less likely for patients who initially had higher House-Brackmann scores.\textsuperscript{[10]}

Patients with comorbid disease(s) had poorer prognoses than those without comorbid disease(s). This can be attributable to the presence of diabetic neuropathy. In our study, comorbid disease had lower recovery rate. Yeo et al. found that recovery rates were significantly lower in patients with comorbid disease(s).\textsuperscript{[11]}

Electroneurography is usually used to measure nerve injury and disease progression in facial palsy. Electroneurography is generally effective when performed more than 3 days after the onset of palsy, when neural damage can be accurately determined.\textsuperscript{[8]} We performed EnoG, 3 days after the onset and found a relationship between ENoG results and patient prognosis. Anpalahan et al. reported that ENoG correctly predicted recovery in 98% of their patients when the neural response of the affected side was more than 25% of the unaffected side.\textsuperscript{[12]} Based on the data of Byun et al., non-recovery is predicted in patients with ENoG values greater than 78% in RHS.\textsuperscript{[13]} Morishima et al. also reported the prognostic value of ENoG in RHS.\textsuperscript{[14]}

Conclusion

Combined treatment in RHS is the treatment of choice. Patients with comorbid disease(s) in RHS have poorer prognosis. In addition, initial House-Brackmann grades of ≥V and worse ENoG response results in lower recovery rates.

Conflict of Interest: No conflicts declared.

References